Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF.

Détails

ID Serval
serval:BIB_729F705AAEA1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF.
Périodique
Human Gene Therapy
Auteur(s)
Aebischer P., Pochon N.A., Heyd B., Deglon N., Joseph J.M., Zurn A.D., Baetge E.E., Hammang J.P., Goddard M., Lysaght M., Kaplan F., Kato A.C., Schluep M., Hirt L., Regli F., Porchet F., De Tribolet N.
ISSN
1043-0342 (Print)
ISSN-L
1043-0342
Statut éditorial
Publié
Date de publication
05/1996
Peer-reviewed
Oui
Volume
7
Numéro
7
Pages
851-860
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
The gene therapy approach presented in this protocol employs a polymer encapsulated, xenogenic, transfected cell line to release human ciliary neurotrophic factor (hCNTF) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A tethered device, containing around 10(6) genetically modified cells surrounded by a semipermeable membrane, is implanted intrathecally; it provides for slow continuous release of hCNTF at a rate of 0.25 to 1.0 micrograms/24 hours. The semipermeable membrane prevents immunologic rejection of the cells and interposes a physical, virally impermeable barrier between cells and host. Moreover, the device and the cells it contains may be retrieved in the event of side effects. A vector containing the human CNTF gene was transfected into a line of baby hamster kidney cells (BHK) with calcium phosphate using a dihydrofolate reductase-based selection vector with a SV40 promoter and contains a HSV-tk killer gene. hCNTF is a potent neurotrophic factor which may have utility for the treatment of ALS. Systemic delivery of hCNTF in humans has been frustrated by peripheral side effects, the molecule's short half life, and its inability to cross the blood-brain barrier. The gene therapy approach described in this protocol is expected to mitigate such difficulties by local intrathecal delivery of a known quantity of continuously-synthesized hCNTF from a retrievable implant.
Mots-clé
Amyotrophic Lateral Sclerosis/therapy, Animals, Capsules/chemistry, Capsules/therapeutic use, Cell Line, Cell Transplantation/methods, Cells, Cultured, Ciliary Neurotrophic Factor, Clinical Protocols, Cricetinae, Ganciclovir/pharmacology, Genetic Therapy/methods, Genetic Vectors/genetics, Genetic Vectors/pharmacology, Humans, Kidney/cytology, Nerve Tissue Proteins/adverse effects, Nerve Tissue Proteins/genetics, Polymers/chemistry, Polymers/therapeutic use, Primates, Prostheses and Implants, Rats, Sheep, Simplexvirus/enzymology, Simplexvirus/genetics, Thymidine Kinase/genetics, Transfection
Pubmed
Web of science
Création de la notice
25/01/2008 13:40
Dernière modification de la notice
03/03/2018 18:17
Données d'usage